All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Bookmark this article
Stay up to date with the latest developments in acute lymphoblastic leukemia with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
CONGRESS | #Tandem25
— ALL Hub (@ALL_Hub_) February 13, 2025
Michaela Seng, Duke-NUS Medical School, presented results from a phase I/II of CART2219.1 in R/R B-ALL. CR/CRi occurred in 100% of pts at Day 28. In all B-ALL pts, 24 month OS was 73%, median LFS and OS was not reached at 24 months. #ALL #ALLsm pic.twitter.com/jsqqNUP9H1
CONGRESS | #Tandem25
— ALL Hub (@ALL_Hub_) February 13, 2025
Karamjeet Sandhu, @cityofhope discussed outcomes after obe-cel treatment in R/R B-ALL. Neutrophil and platelet recovery were delayed in high-risk pts. CAR-HT risk score correlated with disease burden, however use of ALL-HT can identify more patients as… pic.twitter.com/5ANXaFCLyy
CONGRESS | #Tandem25 @YValtis, @MSKCancerCenter discussed use of CAR-HT and ALL-HT to predict outcomes in pts with R/R ALL treated with brexu-cel. Both predicted toxicity, response, and survival, with ALL-HT incorporating disease burden. #ALL #ALLsm https://t.co/zjA6okvwDk pic.twitter.com/lhOj0C4CmL
— ALL Hub (@ALL_Hub_) February 13, 2025
CONGRESS | #Tandem25 @MelodySmithMD, @StanfordMed presented data from a phase I study of ORCA-T and CD19/CD22 CAR T cells in pts with B-ALL. In 14 treated pts, none developed #GvHD or severe CAR-related toxicities. The study is ongoing. #ALL #ALLsmhttps://t.co/zjA6okuYNM pic.twitter.com/CHRIp0maVU
— ALL Hub (@ALL_Hub_) February 14, 2025
CONGRESS | #Tandem25 @DrMonzrAlMalki, @cityofhope presented results from the phase I Alloha trial of TSC-100 & TSC-101 in #AML, #ALL and #MDS post allo-HCT. Infusions were well tolerated with no DLTs. 8% of TSC treated pts relapsed vs 33% in the control arm.… pic.twitter.com/r4O6LODicw
— ALL Hub (@ALL_Hub_) February 16, 2025
CONGRESS | #Tandem25
— ALL Hub (@ALL_Hub_) February 16, 2025
Swati Naik, @StJudeResearch discussed using T-cell add back and prophylactic blinatumomab in pediatric pts with #ALL and #AML. Add back of T-cells was well-tolerated, and blina use was feasible and safe. https://t.co/zjA6okuYNM pic.twitter.com/vza9VawrLj
More about...
Your opinion matters
22 votes - 85 days left ...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox